75694-0

Human papilloma virus 18+45 E6+E7 mRNA [Presence] in Cervix by NAA with probe detection

Active

Term Description

Detects E6/E7 viral messenger RNA (mRNA) of human papillomavirus (HPV) types 18 and 45 in cervical specimens from women with positive HPV assay results. E6/E7 oncogenes must be expressed for malignant transformation. For women 21-years and older with atypical squamous cells of undetermined significance (ASC-US) cervical cytology results, and HPV positive assay results, this assay can be used to assess the presence or absence of high-risk HPV genotypes 18, and/or 45. For women 30-years and older, the HPV 18, and/or 45 genotype assay can be used to test samples from women with HPV assay positive results, along with cervical cytology results. This assay has not been evaluated for HPV vaccinated patients or in cases of suspected abuse. It does not differentiate HPV 18 and HPV 45. This term was created for, but not limited in use to, the Aptima HPV 16 18/45 genotype assay which uses target capture, target amplification by transcription-mediated amplification and detection of the amplification products by hybridization protection. To report results for HPV 16 see Human papilloma virus 16 E6+E7 mRNA [Presence] in Cervix by Probe and signal amplification method [LOINC: 82456-5].
Source: Regenstrief LOINC

Part Description

LP185927-3   Human papilloma virus 18+45 E6+E7 mRNA
HPV type 16 and 18 are the most common carcinogenic HPV types. HPV type 16 is detected in about 50% of invasive cervical cancers worldwide and is associated with a higher risk of a severe cervical intraepithelial neoplasia (CIN 3). HPV type 16 is one of the greatest risks for HPV persistence along with increasing age, smoking, immunosuppression, inflammation, hormones, and genetic factors. HPV type 18 is detected in 10% to 20% of invasive cervical cancers and more commonly found in adenocarcinomas compared to squamous-cell cervical carcinomas. PMID: 19061814 Source: Regenstrief LOINC, PMID: 19061814

Fully-Specified Name

Component

Human papilloma virus 18+45 E6+E7 mRNA

Property

PrThr

Time

Pt

System

Cvx

Scale

Ord

Method

Probe.amp.tar

Additional Names

Short Name

HPV18+45 E6+E7 mRNA Cvx Ql NAA+probe

Display Name

HPV 18+45 E6+E7 mRNA NAA+probe Ql (Cvx)

Consumer Name Alpha Get Info

HPV 18+45 E6+E7 MRNA, Cervix

Example Answer List: LL360-9

Basic Attributes

Class

MICRO

Type

Laboratory

First Released

Version 2.50

Last Updated

Version 2.73

Change Reason

The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. Changed the method from 'Probe.amp.sig' to 'Probe.amp.tar' to correctly reflex the HPA procedure.

Order vs. Observation

Both

Common Test Rank Get Info

3814

Member of these Panels

Language Variants Get Info

Related Names

• 3 Self-Sustaining Sequence Replication
• 3SR SR
• Amplif
• Amplification
• Amplified
• Cervix
• DNA NUCLEIC ACID PROBE
• DNA probe
• Genital tract
• Genital warts
• Gyn
• Gynecology
• HPV
• HPV 18
• HPV 45
• HPV18
• HPV18+45 E6+E7 mRNA
• Human papilloma virus
• Human papillomavirus
• ID
• Infectious Disease
• InfectiousDisease
• LAT
• LCR
• Ligase chain reaction
• Ligation-activated transcription
• Microbiology
• NAA+probe
• NAAT
• NASBA
• Nucleic acid sequence based analysis
• OB
• ObGyn
• Obstetrics
• Ordinal
• Papilloma virus high risk
• PCR
• Point in time
• Polymerase chain reaction
• PR
• Probe amp
• Probe with ampification
• Probe with target amplification
• QBR
• QL
• Qual
• Qualitative
• Random
• Screen
• SDA
• Strand Displacement Amplification
• TMA
• Transcription mediated amplification

LOINC Terminology Service (API) using HL7^® FHIR^® Get Info

Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.

CodeSystem lookup

https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=75694-0

Third Party Copyright

This material includes SNOMED Clinical Terms® (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO) under license. All rights reserved. SNOMED CT® was originally created by The College of American Pathologists. "SNOMED" and "SNOMED CT" are registered trademarks of the IHTSDO.

This material includes content from the US Edition to SNOMED CT, which is developed and maintained by the U.S. National Library of Medicine and is available to authorized UMLS Metathesaurus Licensees from the UTS Downloads site at https://uts.nlm.nih.gov.

Use of SNOMED CT content is subject to the terms and conditions set forth in the SNOMED CT Affiliate License Agreement. It is the responsibility of those implementing this product to ensure they are appropriately licensed and for more information on the license, including how to register as an Affiliate Licensee, please refer to http://www.snomed.org/snomed-ct/get-snomed-ct or info@snomed.org<mailto:info@snomed.org>. This may incur a fee in SNOMED International non-Member countries.

LOINC Copyright

Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © 1995-2024, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.